Division of Amgen Inc.
Latest From Micromet Inc.
Amgen oncology development VP Greg Friberg talked to Scrip about the company's rapidly growing oncology portfolio. "This is our renaissance," he said.
TCR2 Therapeutics raised a $125m Series B round to take two T-cell receptor (TCR)-based therapies into the clinic for solid tumors. The company's technology platform overcomes HLA-matching issues to make TCR-based treatments available to more patients.
The next two years will be important as Amgen looks to deliver on its BiTE platform beyond the first approved drug, Blincyto. SVP David Reese lays out the path forward, including solid tumor opportunities and next-generation BiTEs.
- Large Molecule
- Therapeutic Areas
- Micromet AG
- North America
- Parent & Subsidiaries
- Amgen Inc.
- Senior Management
Patrick A Baeuerle, PhD, SVP, CSO
Jan Fagerberg, MD, PhD, SVP, CMO
Joseph Lobacki, Chief Commercial Officer
- Contact Info
Phone: (240) 752-1420
9201 Corp. Blvd.
Rockville, MD 20850
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.